© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Afatinib is known in chemical circles as N-4-(3-Chloro-4-Fluorophenyl)amino-7-[(3S)-tetrahydro-3-furanyl]oxy-6-quinazolinyl-4-(dimethylamino)-2-butenamide, a mouthful for most, but a vital molecule in targeted cancer treatments. This compound belongs to the class of tyrosine kinase inhibitors and acts against the epidermal growth factor receptor (EGFR) family. Investigators and clinicians focus on afatinib’s role in non-small cell lung cancer, with a growing record for patient outcomes as it addresses certain mutations that typical chemotherapy struggles to reach. Its presence in labs and clinics traces back to its molecular design—every atom put together with purpose.
Afatinib usually appears as a solid—most often as an off-white to light yellow crystalline powder. Sometimes you meet it in flakes, and it rarely strays into near-pearl or granular forms. Don’t expect to see this as a liquid unless formulated for further processing. The solid feels fine and sometimes silky. Under the microscope, tiny crystalline structures shimmer with a faint, pale hue that speaks to purity and careful handling in the lab. Density measures around 1.3 g/cm³, consistent with similar quinazoline-based molecules. It dissolves with difficulty in water, more comfortably in DMSO or dimethylformamide, and reaches solutions up to concentrations needed for research trials.
Afatinib’s backbone includes a quinazoline core, tethered to together by (3-chloro-4-fluorophenyl) and tetrahydro-3-furanyl groups. The molecular formula stands as C24H25ClFN5O3. Seeing its atoms arranged in a 3D model really shows off the careful hand of the synthetic chemist: fused rings, halogen atoms, and the distinctive dimethylamino-butenamide moiety give the structure its properties. Each group isn’t just decorative—chlorine and fluorine shift metabolism, binding, and pharmacokinetics. In this business, even a single atom swap means a world of difference for a drug’s success in the human body.
Labs running quality control demand strict specifications. Purity typically exceeds 98%, checked via HPLC and NMR. Moisture content stays below 0.5%, and the melting point ranges between 240°C and 248°C, helping researchers verify shipment authenticity. Solutions made in appropriate solvents support bioassays and chemical screening. Physical material comes in tightly sealed vials, portions counted by milligrams and grams. Molecular weight clocks in at 485.94 g/mol, matching the theoretical count sampled from rigorous analysis.
Afatinib, as a pharmaceutical raw material, falls under HS Code 2934999099, the global tariff categorization for other heterocyclic compounds. Regulatory paperwork accompanies nearly every shipment, given its use as an active ingredient for prescription cancer therapies. Material safety data sheets (MSDS) summarize transport risks and set the baseline for customs officials and warehouse protocols. Handling in an industrial context means reporting to local and national authorities, keeping a careful ledger for hazard communication.
Afatinib’s pharmacology demands respect for safety. As with most molecular inhibitors, it brings health hazards on accidental exposure, inhalation, or skin contact. Research experience shows that raw material can irritate mucous membranes and prove toxic in sufficient doses. Standard procedure calls for gloves, eye protection, and controlled ventilation during weighing or formulation. Disposal must follow hazardous chemical waste routes due to both environmental persistence and bioactivity. Chronic exposure assessments point toward target organ effects, making containment and careful record-keeping necessary throughout handling and processing.
Synthesizing afatinib starts far upstream from the final product. Raw materials encompass simple organic fragments like anilines, halogenated aromatics, and furan intermediates. Each batch journey is tracked, from procurement through synthesis and purification, building assurance in reproducibility and quality. Analytical chemists keep a tight grip on intermediates, screening for potential impurities which would undermine both safety and clinical effectiveness. Finished afatinib then moves toward formulation, where blending into tablets or solution marks the step before hitting clinic shelves.
Experience with powdered pharmaceutical agents shapes how one stores and manages afatinib. Product stays sealed against air and moisture, tucked away in cool, dark environments around 2–8°C. Security focuses on preventing cross contamination and maintaining an unbroken cold chain. Technicians and scientists depend on these basics to stop degradation that would alter the molecule or reduce activity. Homogeneity throughout containers—whether by lot or production number—gets checked by regular sampling, alignment with regulatory records, and cross-checks between inventories.
Reducing hazards in afatinib’s supply chain means tighter controls on raw starting materials and improved personal protective equipment for handlers. Automated weighing and dispensing lessen the risk of user exposure. Digital record-keeping strengthens tracking, from synthesis through inventory, giving downstream users quick access to batch information. Some labs advocate closed-system transfers and local air extraction in dispersion zones to cut inhalation risk. Ultimately, strengthening education and compliance through ongoing training keeps standards high and brings new researchers up to speed—with oversight agencies pushing the industry to keep pace with evolving best practices.
